Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The impact of disease duration on improvements in ACR responses and remission following abatacept treatment in patients with an inadequate response 2 to anti-TNF therapy in the ATTAIN trial. 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals Genovese, M., Luggen, M., Kremer, J., Sany, J., Aranda, R., Becker, J. C., White, A., Schiff, M., Dougados, M. WILEY-BLACKWELL. 2005: S137–S137
View details for Web of Science ID 000232207800296